Member Info for RSPCooper

What the hell are these people talking about shorts on

Read Simon Cawkswells book Evils good and educate yourselves.

Hopefully we don't need 3.8 Billion funding might be a bit too much dilution.

The 61404 trade is a buy incorrectly reported as a sell.

Just went into both Derby and Ashbourne stores to get gift vouchers for our staff, Both stores SIX days before xmas had none available, staff getting M and S vouchers now.Not just management at board level that need to get their finger out.

Yeah we get it.

Hope you are still holding its good to have the last laugh.Perfect illustration that a bit of patience often pays off.Nice to see placing is at a sensible level as well.

Actually looking at delayed trade they might just be right.

Dont worry be happy says the BOD.

Mail a friend Tuesday 18 January, 2011 Ondine Boipharma Cor UCL & Ondine Awarded £1 Million by UK Medi... FOR: ONDINE BIOMEDICAL INC. TSX, AIM SYMBOL: OBP January 18, 2011 UCL & Ondine Awarded £1 Million by UK Medical Research Council to Develop Infection Prevention Technology for Catheters VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 18, 2011) - Ondine Biomedical Inc. ("Ondine" or the "Company") (TSX:OBP)(AIM:OBP) today announced that University College London (UCL) Professors Ivan P. Parkin and Michael Wilson and colleagues, in collaboration with Ondine, have been awarded a Medical Research Council (MRC) Developmental Pathway Funding Scheme Award of GBP 1 million to develop a light activated antimicrobial application for the prevention of catheter-associated infections such as urinary tract infections. This two and one-half year project is scheduled to initiate on February 1, 2011, and represents the first of its kind for Ondine. This project will be managed by Professor Ivan Parkin, Head of the Department of Chemistry, UCL, and Professor Michael Wilson, Professor of Microbiology, UCL Eastman Dental Institute ("UCLEDI"), to take existing fundamental basic and clinical research findings towards the clinic. The stated purpose of the Award is to help strengthen the translation of fundamental research towards patient benefit. This project is intended to enhance the exclusive license that Ondine has with University College London on Light-Activated Antimicrobial Agents nanoparticle conjugates and mixtures, and leverages expertise acquired by Ondine during the development of Endowave(TM), a ventilator associated pneumonia (VAP) prevention product and MRSAid(TM), a MRSA nasal decolonization product based on photodynamic disinfection. "We consider this initiative to be a significant step towards the development of a major class of new medical devices that may have the potential to reduce the number of urinary tract infections acquired in hospital, thereby significantly reducing healthcare costs," stated Professor Ivan Parkin. "Furthermore, proof of concept for application to urinary catheters will demonstrate a step-change in the prevention of catheter associated infections (CAIs) and provide opportunity for the potential application of this novel approach to other catheter types, including Cardiovascular, Intravenous & Neurovascular catheters." Professor Michael Wilson, Professor of Microbiology, UCLEDI, and Pro-Provost for Europe at UCL, stated: "What makes this undertaking unique is that the development work will be carried out by a multi-disciplinary team from clinics, academia and industry consisting of chemists, bacteriologists, photobiologists, medical laser physicists and clinicians experienced in the management of catheter-associated infections. This level of collaboration across a number of disciplines i

In 3.5 months bought at 80p.Maybe not one for an in and out daytrader but it sure as hell beats the building society.

Tomorrow this is a very quite board considering recent rises. Solid company with good fundementals.

You still in here? Decent tick up today.Very off the radar with amazing NAV for an aimer.